ABSTRACT
Hemoglobin A[HbA] has been used for decades to monitor the control of glycemia in diabetes. Although HbA1c is currently undergoing a reassessment, and major developments have been underway in recent years, HbA1c is not recommended at present for diabetes screening or diagnosis. The objective of this review is to summarize the recent developments and to review a potential diagnostic role for HbA1c. Implementation of changes in HbA1c results and units of measurements have been suggested for the purpose of test standardization. These include lower reference ranges [by about 1.5-2 points] and measurement units expressed in percentage [%], as mg/dL [mmol/L] or mmol/mol [or a combination of these units]. In diabetes screening and diagnosis, the current diagnostic guidelines use measurement of plasma glucose either fasting or after glucose load. These diagnostic methods have shortcomings warranting a potential diagnostic role for HbA1c. While recent developments in HbA1c methodologies are acknowledged, it is not yet known which changes will be implemented, and how soon. Given the recent literature supporting HbA1c diagnostic abilities, and given the shortcomings of the current guidelines, it is possible that a diagnostic role for HbA1c may be considered in future practice guidelines, globally. Very recently, the first of such recommendations has been proposed by an expert panel, as announced by the US Endocrine Society